WO2002012447A3 - Isolation and use of solid tumor stem cells - Google Patents

Isolation and use of solid tumor stem cells Download PDF

Info

Publication number
WO2002012447A3
WO2002012447A3 PCT/US2001/024243 US0124243W WO0212447A3 WO 2002012447 A3 WO2002012447 A3 WO 2002012447A3 US 0124243 W US0124243 W US 0124243W WO 0212447 A3 WO0212447 A3 WO 0212447A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid tumor
stem cells
tumors
tumor stem
cells
Prior art date
Application number
PCT/US2001/024243
Other languages
French (fr)
Other versions
WO2002012447A2 (en
WO2002012447B1 (en
Inventor
Michael F Clarke
Sean J Morrison
Max S Wicha
Muhammad Al-Hajj
Original Assignee
Univ Michigan
Michael F Clarke
Sean J Morrison
Max S Wicha
Muhammad Al-Hajj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP10179961.7A priority Critical patent/EP2359863B1/en
Priority to EP01956101.8A priority patent/EP1343871B1/en
Priority to JP2002517738A priority patent/JP5352037B2/en
Priority to US10/343,692 priority patent/US7115360B2/en
Priority to AU7813401A priority patent/AU7813401A/en
Priority to ES01956101.8T priority patent/ES2553796T3/en
Priority to CA2417909A priority patent/CA2417909C/en
Priority to AU2001278134A priority patent/AU2001278134B2/en
Application filed by Univ Michigan, Michael F Clarke, Sean J Morrison, Max S Wicha, Muhammad Al-Hajj filed Critical Univ Michigan
Publication of WO2002012447A2 publication Critical patent/WO2002012447A2/en
Publication of WO2002012447A3 publication Critical patent/WO2002012447A3/en
Publication of WO2002012447B1 publication Critical patent/WO2002012447B1/en
Priority to US11/529,869 priority patent/US7850961B2/en
Priority to US11/607,780 priority patent/US7754206B2/en
Priority to US11/651,214 priority patent/US20090004205A1/en
Priority to US11/788,489 priority patent/US20080194022A1/en
Priority to US11/776,935 priority patent/US8044259B2/en
Priority to US12/758,540 priority patent/US20110033481A1/en
Priority to US12/979,991 priority patent/US8357491B2/en
Priority to US13/241,701 priority patent/US8420885B2/en
Priority to US13/563,884 priority patent/US20120295350A1/en
Priority to US13/714,921 priority patent/US20140011274A1/en
Priority to US13/795,381 priority patent/US9089556B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Abstract

A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
PCT/US2001/024243 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells WO2002012447A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EP01956101.8A EP1343871B1 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
JP2002517738A JP5352037B2 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
US10/343,692 US7115360B2 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
AU7813401A AU7813401A (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
ES01956101.8T ES2553796T3 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
EP10179961.7A EP2359863B1 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
CA2417909A CA2417909C (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
AU2001278134A AU2001278134B2 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
US11/529,869 US7850961B2 (en) 2000-08-03 2006-09-29 Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist
US11/607,780 US7754206B2 (en) 2000-08-03 2006-12-01 Method for treating cancer using a Notch4 ligand antagonist
US11/651,214 US20090004205A1 (en) 2000-08-03 2007-01-09 Prospective identification and characterization of breast cancer stem cells
US11/788,489 US20080194022A1 (en) 2000-08-03 2007-04-20 Isolation and use of solid tumor stem cells
US11/776,935 US8044259B2 (en) 2000-08-03 2007-07-12 Determining the capability of a test compound to affect solid tumor stem cells
US12/758,540 US20110033481A1 (en) 2000-08-03 2010-04-12 Prospective identification and characterization of breast cancer stem cells
US12/979,991 US8357491B2 (en) 2000-08-03 2010-12-28 Isolation and use of solid tumor stem cells
US13/241,701 US8420885B2 (en) 2000-08-03 2011-09-23 Determining the capability of a test compound to affect solid tumor stem cells
US13/563,884 US20120295350A1 (en) 2000-08-03 2012-08-01 Prospective Identification and Characterization of Breast Cancer Stem Cells
US13/714,921 US20140011274A1 (en) 2000-08-03 2012-12-14 Isolation and use of solid tumor stem cells
US13/795,381 US9089556B2 (en) 2000-08-03 2013-03-12 Method for treating cancer using an antibody that inhibits notch4 signaling

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22279400P 2000-08-03 2000-08-03
US60/222,794 2000-08-03
US24031700P 2000-10-13 2000-10-13
US60/240,317 2000-10-13
US09/920,517 US6984522B2 (en) 2000-08-03 2001-08-01 Isolation and use of solid tumor stem cells
US09/920,517 2001-08-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/920,517 Continuation US6984522B2 (en) 2000-08-03 2001-08-01 Isolation and use of solid tumor stem cells

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/343,692 A-371-Of-International US7115360B2 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells
US10343692 A-371-Of-International 2001-08-02
US11/529,869 Continuation US7850961B2 (en) 2000-08-03 2006-09-29 Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist

Publications (3)

Publication Number Publication Date
WO2002012447A2 WO2002012447A2 (en) 2002-02-14
WO2002012447A3 true WO2002012447A3 (en) 2003-04-24
WO2002012447B1 WO2002012447B1 (en) 2003-07-03

Family

ID=27397140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024243 WO2002012447A2 (en) 2000-08-03 2001-08-02 Isolation and use of solid tumor stem cells

Country Status (7)

Country Link
US (13) US6984522B2 (en)
EP (2) EP2359863B1 (en)
JP (1) JP5352037B2 (en)
AU (2) AU7813401A (en)
CA (1) CA2417909C (en)
ES (1) ES2553796T3 (en)
WO (1) WO2002012447A2 (en)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2469204A1 (en) * 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
WO2003089580A2 (en) * 2002-04-16 2003-10-30 Dana-Farber Cancer Institute, Inc. Cancer models
JP2006501449A (en) 2002-09-27 2006-01-12 ザ ジェネラル ホスピタル コーポレーション Microfluidic device for cell separation and use thereof
US20060084599A1 (en) * 2003-03-05 2006-04-20 Maine Medical Center Compositions, methods and kits relating to notch signaling
WO2004090110A2 (en) * 2003-03-31 2004-10-21 Bresagen Inc. Compositions and methods for the control, differentiation and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway
US20040265281A1 (en) * 2003-04-07 2004-12-30 Denis Rodgerson System capable of treating and defining various diseases using stem cells
GB0310191D0 (en) * 2003-05-02 2003-06-04 Cytovation As Method of generating and isolating tumour cells
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
EP1641914B1 (en) 2003-06-27 2016-07-20 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US20050193432A1 (en) * 2003-11-18 2005-09-01 Whitehead Institute For Biomedical Research Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof
US20050232927A1 (en) * 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
CN1950518A (en) 2004-02-03 2007-04-18 密执安州立大学董事会 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20060121624A1 (en) * 2004-03-03 2006-06-08 Huang Lotien R Methods and systems for fluid delivery
EP1765503A2 (en) * 2004-03-03 2007-03-28 The General Hospital Corporation System for delivering a diluted solution
US8252591B2 (en) 2004-05-07 2012-08-28 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
NZ551828A (en) * 2004-05-12 2009-03-31 Inst Medical W & E Hall A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
US8067230B2 (en) * 2004-05-14 2011-11-29 New York University Prostatic stem cells, isolation and uses
EP1774325B1 (en) * 2004-06-17 2016-02-24 Massachusetts Institute of Technology Methods for identifying stem cells based on nuclear morphotypes
US7989001B2 (en) * 2004-09-13 2011-08-02 Untae Kim Method of separating tumor cells with and without lymphotropic metastatic potential in a human carcinoma
ITRM20040438A1 (en) * 2004-09-15 2004-12-15 Univ Palermo METHOD FOR PURIFICATION AND AMPLIFICATION OF CANCER STEM CELLS.
GB0421838D0 (en) * 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
WO2006047878A1 (en) * 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
US10538742B2 (en) * 2004-11-12 2020-01-21 Cambridge Enterprise Limited Methods and means related to cancer stem cells
WO2006071802A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
US20070026418A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
JP5757495B2 (en) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド Use of TNF inhibitors for the treatment of erosive polyarthritis
EP1726208A3 (en) * 2005-05-24 2007-02-28 Centro de Investigacion Biomolecular Aplicada S.L. Murine stem cells and applications thereof
WO2007044091A2 (en) * 2005-06-02 2007-04-19 Fluidigm Corporation Analysis using microfluidic partitioning devices
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP5405824B2 (en) 2005-06-30 2014-02-05 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ Progenitor cells and uses thereof
US20070044168A1 (en) * 2005-07-12 2007-02-22 Northwestern University Transplantable tumor model
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070059680A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for cell enrichment
US20070059719A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Business methods for prenatal Diagnosis
US20070059716A1 (en) * 2005-09-15 2007-03-15 Ulysses Balis Methods for detecting fetal abnormality
US20070220621A1 (en) * 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
DE102005052384B4 (en) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for the detection, labeling and treatment of epithelial lung tumor cells and means for carrying out the method
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP1963490A2 (en) * 2005-12-09 2008-09-03 Massachussets Institute of Technology Methods for identifying and targeting tumor stem cells based on nuclear morphology
PT1962895E (en) * 2005-12-16 2013-03-28 Regeneron Pharma Therapeutic use of a dll4 antagonist and a vegf inhibitor for inhibiting tumor growth
PL1971681T3 (en) 2005-12-16 2018-01-31 Depuy Synthes Products Inc Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
JP5179376B2 (en) * 2005-12-19 2013-04-10 エシコン・インコーポレイテッド In vitro growth of postpartum-extracted cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
CA2646127A1 (en) * 2006-03-16 2007-09-27 Health Research Inc. Inhibition of breast carcinoma stem cell growth and metastasis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007134274A2 (en) * 2006-05-12 2007-11-22 Attenuon, Llc Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
JP2009539403A (en) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosing and treating cancer
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc Use of highly parallel snp genotyping for fetal diagnosis
WO2007147018A1 (en) * 2006-06-14 2007-12-21 Cellpoint Diagnostics, Inc. Analysis of rare cell-enriched samples
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
WO2007147165A2 (en) * 2006-06-16 2007-12-21 Bresagen, Inc. Human cancer stem cell culture compositions comprising erbb2 variants and methods of use thereof
CA2659231A1 (en) * 2006-07-28 2008-01-31 Chundsell Medicals Ab Embryonic stem cell markers for cancer diagnosis and prognosis
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
CA2698597A1 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Monitoring cancer stem cells
WO2008030538A2 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
US20080187938A1 (en) * 2006-09-22 2008-08-07 The Regents Of The University Of Michigan ALDH1 As A Cancer Stem Cell Marker
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700579A1 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
ME02371B (en) 2006-09-29 2016-06-20 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
ITMI20062100A1 (en) * 2006-10-31 2008-05-01 Fondazione I R C C S Istituto Neurologico METHOD FOR THE STIMULATION OF DENDRITIC CELLS AND CELL PRODUCT SO OBTAINED FOR AUTOLOGOUS IMMUNOTHERAPY OF HUMAN SOLID TUMORS
US8765390B2 (en) * 2006-12-08 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of squamous carcinoma stem cells
TWI419904B (en) 2006-12-18 2013-12-21 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EA017613B1 (en) 2006-12-20 2013-01-30 Новаркс Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
JP2010516259A (en) * 2007-01-22 2010-05-20 レイベン バイオテクノロジーズ Human cancer stem cells
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2115456A2 (en) * 2007-02-01 2009-11-11 Dana-Farber Cancer Institute, Inc. Cell co-culture systems and uses thereof
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
WO2008143795A1 (en) * 2007-05-11 2008-11-27 Champions Biotechnology, Inc. Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing
WO2008140751A1 (en) * 2007-05-11 2008-11-20 Champions Biotechnology, Inc. Human leiosarcoma and non small cell lung cancer lung xenograft models
JP5190861B2 (en) * 2007-05-11 2013-04-24 オリンパス株式会社 Biological tissue decomposition method
EP2155249A4 (en) * 2007-05-15 2011-11-16 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
WO2008156629A2 (en) * 2007-06-13 2008-12-24 Massachusetts Institute Of Technology Methods and agents for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells
US8642306B2 (en) * 2007-06-14 2014-02-04 Mitsui Engineering & Shipbuilding Co., Ltd. Flow cytometer having cell-sorting function and method of separating living cells
SI2173379T1 (en) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2676678A1 (en) * 2007-07-17 2013-12-25 The General Hospital Corporation Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof
EP2188367A4 (en) 2007-08-10 2010-10-27 Whitehead Biomedical Inst Hormone responsive tissue culture system and uses thereof
EP2037265A1 (en) * 2007-09-17 2009-03-18 Adnagen AG Solid phase cell isolation and/or enrichment method
EP2188630A4 (en) * 2007-10-02 2010-11-03 Univ Rochester Methods and compositions related to synergistic responses to oncogenic mutations
AU2008308531B2 (en) 2007-10-05 2014-04-24 Ethicon, Incorporated Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
WO2009097135A1 (en) * 2008-02-01 2009-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating carcinoma stem cells
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (en) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1 receptor binding agents and methods of use thereof
WO2010011893A1 (en) * 2008-07-24 2010-01-28 University Of Central Florida Research Foundation, Inc. Therapy targeting cancer stem cells
ES2565779T3 (en) * 2008-09-02 2016-04-06 Cedars-Sinai Medical Center CD133 epitopes
CA2735900A1 (en) * 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
EP2952589B1 (en) 2008-09-20 2018-02-14 The Board of Trustees of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
TWI506037B (en) 2008-09-26 2015-11-01 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
US20110256110A1 (en) * 2008-10-24 2011-10-20 Children's Hospital Los Angeles Amniotic fluid cells and uses thereof
CN104634972B (en) 2008-11-11 2017-06-13 密执安大学评议会 Anti- CXCR1 compositions and method
AU2009327384B2 (en) 2008-12-19 2014-07-10 DePuy Synthes Products, LLC Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
US20110311494A1 (en) 2009-02-26 2011-12-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of reprogramming renal cells
US8170320B2 (en) * 2009-03-03 2012-05-01 Hologic, Inc. Mammography/tomosynthesis systems and methods automatically deriving breast characteristics from breast x-ray images and automatically adjusting image processing parameters accordingly
US8762069B2 (en) * 2009-03-11 2014-06-24 Institute for Medical Biomathematics Therapeutic implications of dickkopf affecting cancer stem cell fate
CN102498204B (en) 2009-03-26 2015-02-04 德普伊新特斯产品有限责任公司 Human umbilical cord tissue cells as therapy for Alzheimer's disease
WO2010129895A2 (en) * 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
JP5965318B2 (en) 2009-10-16 2016-08-03 オンコメッド ファーマシューティカルズ インコーポレイテッド Therapeutic combinations of DLL4 antagonists and antihypertensive agents and methods of treatment therewith
CN102770530A (en) * 2009-11-05 2012-11-07 斯隆-凯特林癌症研究院 Catenae: serosal cancer stem cells
WO2011063237A2 (en) 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
EP2506875A4 (en) * 2009-12-01 2013-11-27 Oncomed Pharm Inc Methods for treating cancers comprising k-ras mutations
EP2517555A4 (en) * 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US20110312503A1 (en) 2010-01-23 2011-12-22 Artemis Health, Inc. Methods of fetal abnormality detection
JP5847733B2 (en) 2010-01-28 2016-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Hanging drop array plate
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
DK2596119T3 (en) 2010-07-23 2021-07-26 Astellas Inst For Regenerative Medicine METHODS FOR DETECTING RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP2013541951A (en) 2010-10-01 2013-11-21 アメリカ合衆国 Manipulation of stem cell function by p53 isoform
JP6230789B2 (en) 2010-10-06 2017-11-15 中外製薬株式会社 Cancer stem cell population and method for producing the same
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CN103354905A (en) 2010-10-25 2013-10-16 麻省理工学院 Wound healing metakaryotic stem cells and methods of use thereof
US8912156B1 (en) 2011-02-04 2014-12-16 Whitehead Institute For Biomedical Research Markers for and methods of targeting tumor stem cells
WO2012167101A1 (en) 2011-06-03 2012-12-06 The General Hospital Corporation Ovarian cancer stem cells and methods of isolation and uses thereof
MX349198B (en) 2011-07-15 2017-07-18 Oncomed Pharmaceuticals Inc * Rspo binding agents and uses thereof.
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
AU2012358810B2 (en) 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
DK2817620T3 (en) * 2012-02-22 2016-09-05 Verik Bio Inc IMMUNTERY TREATMENT SYSTEM FOR TUMOR FORMATION AND PROGRESSION
US20140147861A1 (en) * 2012-05-04 2014-05-29 The Regents of the University of Califomia Markers to identify primary cells from tumor biopsies
WO2013177206A2 (en) 2012-05-21 2013-11-28 Fluidigm Corporation Single-particle analysis of particle populations
NZ704269A (en) 2012-07-13 2016-05-27 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
CN114939119A (en) 2012-08-09 2022-08-26 细胞基因公司 Treatment of immune-related and inflammatory diseases
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
CN104520328B (en) 2012-08-13 2019-06-07 霍夫曼-拉罗奇有限公司 Antialiasing protein antibodies and application method
US20160017293A1 (en) * 2012-08-15 2016-01-21 Neostem Oncology, Llc Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
GB2519717A (en) * 2012-08-15 2015-04-29 California Stem Cell Inc Rapid method production high purity cancer stem cells and population of high purity cancer stem cells
JP2015531240A (en) * 2012-10-09 2015-11-02 ファイブ３・ジェノミクス・エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ System and method for tumor clonality analysis
US10033777B2 (en) * 2012-10-19 2018-07-24 Interdigital Patent Holdings, Inc. Multi-hypothesis rate adaptation for HTTP streaming
CN104768579A (en) 2012-10-23 2015-07-08 昂科梅德制药有限公司 Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
JP6371294B2 (en) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with DLL4 antagonists
EP2950885B1 (en) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
EP2968408A4 (en) * 2013-03-11 2016-11-23 Neostem Oncology Llc Method of induction and purification of a cell population responsible for vasculary mimicry and use of the same
EP2968459A4 (en) * 2013-03-12 2016-10-19 Neostem Oncology Llc Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
SG11201507427QA (en) 2013-03-15 2015-10-29 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
WO2015048305A1 (en) * 2013-09-27 2015-04-02 Vaccinogen, Inc. Autologous tumor vaccines and methods
JP6633522B2 (en) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
EP3097418B1 (en) * 2014-01-20 2021-04-28 National Centre For Cell Science A tumor deconstruction platform for the analysis of intra-tumor heterogeneity
AR099465A1 (en) 2014-02-12 2016-07-27 Genentech Inc ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
JP6783143B2 (en) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド Passive replenishment of medium
TWI745271B (en) 2014-05-19 2021-11-11 美商西建公司 Treatment of systemic lupus erythematosus
SG11201610630RA (en) 2014-06-25 2017-01-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Identification of cancer stem cell markers and use of same for diagnosis and treatment
AU2015317986A1 (en) 2014-09-16 2017-03-09 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
CN106715676A (en) 2014-09-26 2017-05-24 泰尔茂比司特公司 Scheduled feed
ES2808153T3 (en) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Combination therapy for disease treatment
AR104250A1 (en) * 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd ANTI-NOTCH4 HUMAN ANTIBODY
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
TW202127033A (en) * 2017-01-04 2021-07-16 國立臺灣大學 Biomarkers for cancer stem cells
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
WO2020047099A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
CN110487998B (en) * 2019-08-13 2023-01-31 迈克医疗电子有限公司 Parameter optimization method and device for magnetic separation system, analysis instrument and storage medium
WO2021116714A1 (en) * 2019-12-12 2021-06-17 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
RU2735982C2 (en) * 2020-06-02 2020-11-11 Федеральное государственное бюджетное учреждение Method for prediction of radiosensitivity of malignant growths of upper respiratory tract
WO2023225352A2 (en) * 2022-05-20 2023-11-23 Helex Inc. Methods for assessment of effects of gene editing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037004A1 (en) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
WO1998057621A1 (en) * 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction

Family Cites Families (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4089003A (en) * 1977-02-07 1978-05-09 Motorola, Inc. Multifrequency microstrip antenna
US4109496A (en) * 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4411990A (en) 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4584268A (en) 1981-10-13 1986-04-22 Ceriani Roberto Luis Method and compositions for carcinoma diagnosis
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4960716A (en) 1984-05-01 1990-10-02 Ciba Corning Diagnostics Corp. Monoclonal antibodies specific for 330 KD breast tumor antigen and assay using said monoclonal antibodies
US5019497A (en) * 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4751177A (en) 1985-06-13 1988-06-14 Amgen Methods and kits for performing nucleic acid hybridization assays
EP0228075B1 (en) 1986-01-03 1991-04-03 Molecular Diagnostics, Inc. Eucaryotic genomic dna dot-blot hybridization method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4877745A (en) 1986-11-17 1989-10-31 Abbott Laboratories Apparatus and process for reagent fluid dispensing and printing
GB2198290B (en) * 1986-11-29 1990-05-09 Stc Plc Dual band circularly polarised antenna with hemispherical coverage
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5087570A (en) 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US4981785A (en) * 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) * 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5994617A (en) 1988-09-19 1999-11-30 Hsc Research Development Corporation Engraftment of immune-deficient mice with human cells
CA1335181C (en) 1988-10-11 1995-04-11 R. Alan Hardwick System for selective cell separation from cell concentrate
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
DE68919715T2 (en) 1988-12-28 1995-04-06 Stefan Miltenyi METHOD AND MATERIALS FOR HIGHLY GRADUATED MAGNETIC SPLITTING OF BIOLOGICAL MATERIALS.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5219726A (en) 1989-06-02 1993-06-15 The Salk Institute For Biological Studies Physical mapping of complex genomes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6583115B1 (en) 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
JP2802518B2 (en) * 1989-10-13 1998-09-24 戸田工業株式会社 Magnetic recording media
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) * 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0564531B1 (en) * 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JPH06504997A (en) 1990-12-06 1994-06-09 アフィメトリックス，　インコーポレイテッド Synthesis of immobilized polymers on a very large scale
DK0834576T3 (en) 1990-12-06 2002-04-22 Affymetrix Inc A Delaware Corp Detection of nucleic acid sequences
DE4039677A1 (en) 1990-12-12 1992-06-17 Boehringer Mannheim Gmbh UNIVERSAL BINDING FILM
US5856441A (en) * 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human notch and delta, binding domains in toporythmic proteins, and methods based thereon
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
JP3417558B2 (en) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド Choice of ligand agonists and antagonists
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0534858B2 (en) 1991-09-24 2005-04-27 Keygene N.V. Selective restriction fragment amplification : a general method for DNA fingerprinting
US5753229A (en) * 1991-09-25 1998-05-19 Mordoh; Jose Monoclonal antibodies reactive with tumor proliferating cells
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
DE69233391D1 (en) * 1991-11-07 2004-09-02 Nanotronics Inc Hybridization of polynucleotides conjugated with chromophores and fluorophores to create a donor-donor energy transfer system
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
DE69326967T2 (en) * 1992-01-17 2000-06-15 Lakowicz Joseph R Phase modulation energy transfer fluoroimmunoassay
US5376313A (en) * 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5840484A (en) 1992-07-17 1998-11-24 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5654183A (en) 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
EP0658194A1 (en) 1992-07-27 1995-06-21 California Institute Of Technology Mammalian multipotent neural stem cells
ATE316573T1 (en) 1992-10-30 2006-02-15 Gen Hospital Corp INTERACTING TRAP SYSTEM FOR ISOLATION OF PROTEINS
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JP3106021B2 (en) * 1992-11-30 2000-11-06 キヤノン株式会社 Pattern data compression method and apparatus and output method and apparatus
JP3189279B2 (en) * 1993-02-19 2001-07-16 日本新薬株式会社 Pharmaceutical composition containing nucleic acid copolymer
US5876978A (en) * 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) * 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5744306A (en) 1993-04-19 1998-04-28 Emory University Methods for nucleic acid detection, sequencing, and cloning using exonuclease
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5681860A (en) 1993-09-21 1997-10-28 The Trustees Of Columbia University In The City Of New York Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol
US5674694A (en) 1993-09-21 1997-10-07 Biologic & Immunologic Science Laboratories, Inc. Clonogenic assay for detecting micro levels of tumor cells in hematopoietic samples
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
EP0784690B1 (en) * 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5710000A (en) 1994-09-16 1998-01-20 Affymetrix, Inc. Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
US5567326A (en) 1994-09-19 1996-10-22 Promega Corporation Multisample magnetic separation device
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DK0787200T3 (en) * 1994-10-28 2005-08-15 Univ Pennsylvania Improved adenovirus and methods for its use
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6207147B1 (en) 1996-10-11 2001-03-27 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
KR100479146B1 (en) 1995-04-21 2005-05-16 셀 제네시스, 인코포레이티드 Generation of Large Genomic DNA Deletions
US5610620A (en) * 1995-05-19 1997-03-11 Comant Industries, Inc. Combination antenna
US5753439A (en) 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
AU6261696A (en) * 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
DK1445322T4 (en) * 1995-06-15 2012-09-03 Crucell Holland Bv Packaging systems for human recombinant adenovirus for use in gene therapy
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
DK0861261T3 (en) 1995-06-28 2009-12-14 Imp Cancer Res Tech Nucleotide and protein sequences of vertebrate Delta genes and methods based thereon
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
EP0851925B1 (en) * 1995-09-21 2005-08-03 Genentech, Inc. Human growth hormone variants
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
AU1867397A (en) * 1995-11-16 1997-06-05 Michael W. Dahm Method of quantifying tumour cells in a body fluid and a suitable test kit
AU716889B2 (en) 1995-11-17 2000-03-09 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide
US5598677A (en) * 1995-12-19 1997-02-04 Rehm, Iii; Frederick G. Insulated covering for building sheathing
WO1997023782A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5720722A (en) * 1996-01-11 1998-02-24 Medela, Incorporated Connector for use in single and double breast pumping and breast pump using same
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
AU720890B2 (en) 1996-05-31 2000-06-15 National American Red Cross, The Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5885529A (en) * 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
FR2751986B1 (en) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med GENE INVOLVED IN CADASIL, DIAGNOSTIC METHOD AND THERAPEUTIC APPLICATION
CA2263883C (en) * 1996-08-29 2003-07-08 The Regents Of The University Of California Kuz, a novel family of metalloproteases
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US5859535A (en) * 1997-02-12 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy System for determining size and location of defects in material by use of microwave radiation
SE508356C2 (en) * 1997-02-24 1998-09-28 Ericsson Telefon Ab L M Antenna Installations
US6165709A (en) 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
WO1998039636A1 (en) 1997-03-07 1998-09-11 Clare Chemical Research Llc Fluorometric detection using visible light
US6080912A (en) * 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2285020A1 (en) 1997-04-04 1998-10-15 Millennium Biotherapeutics, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
DE19715484A1 (en) 1997-04-14 1998-10-15 Boehringer Mannheim Gmbh Procedure for applying reagent spots
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5830730A (en) * 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
US5894869A (en) * 1997-05-12 1999-04-20 Crosman Corporation CO2 cartridge pressurization device
AU730782B2 (en) 1997-05-14 2001-03-15 Asahi Kasei Kabushiki Kaisha Novel differentiation-inhibitor
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6136952A (en) * 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
CA2290736A1 (en) 1997-07-11 1999-01-21 Introgene B.V. Interleukin-3 gene therapy for cancer
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6228659B1 (en) 1997-10-31 2001-05-08 PE Corporation (“NY”) Method and apparatus for making arrays
US6197523B1 (en) * 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6183968B1 (en) 1998-03-27 2001-02-06 Incyte Pharmaceuticals, Inc. Composition for the detection of genes encoding receptors and proteins associated with cell proliferation
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5965352A (en) 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
WO2000006726A2 (en) 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
WO2000009675A1 (en) 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
EP1108047A1 (en) 1998-08-27 2001-06-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
GB9819681D0 (en) 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds
US6146830A (en) 1998-09-23 2000-11-14 Rosetta Inpharmatics, Inc. Method for determining the presence of a number of primary targets of a drug
AU768269B2 (en) * 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
WO2000025725A2 (en) 1998-11-02 2000-05-11 Biogen, Inc. Functional antagonists of hedgehog activity
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US6215894B1 (en) 1999-02-26 2001-04-10 General Scanning, Incorporated Automatic imaging and analysis of microarray biochips
AU767066B2 (en) 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20030119029A1 (en) 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
WO2000073337A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. Polymer conjugates of hedgehog proteins and uses
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
WO2001052143A1 (en) 2000-01-10 2001-07-19 Cd Warehouse, Inc. Method and apparatus for arranging for sales using centralized ordering and decentralized shipping
US20040048249A1 (en) 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
JP2003520266A (en) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ-secretase inhibitor
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US20050070578A1 (en) 2000-03-30 2005-03-31 Baxter Anthony David Small organic molecule regulators of cell proliferation
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US7060436B2 (en) 2000-06-17 2006-06-13 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
WO2001098354A2 (en) 2000-06-21 2001-12-27 Incyte Genomics, Inc. Human receptors
US6632620B1 (en) * 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
DE10031380A1 (en) 2000-06-28 2002-01-10 Merck Patent Gmbh Process for the transfer of alkylidene groups to organic compounds
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2001288628A1 (en) 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
WO2002028432A2 (en) * 2000-10-04 2002-04-11 Ca*Tx, Inc. Stem cell-based methods for preventing and treating tumor
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20020169300A1 (en) 2001-01-30 2002-11-14 Waterman Marian L. Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1
US7413873B2 (en) 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US20030064384A1 (en) 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
EP1401431A4 (en) 2001-06-15 2004-07-07 Genentech Inc Human growth hormone antagonists
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040023244A1 (en) 2001-06-21 2004-02-05 Griffin Jennifer A Receptors
WO2003000848A2 (en) * 2001-06-22 2003-01-03 Stemcells, Inc. Liver engrafting cells, assays, and uses thereof
WO2003000893A2 (en) 2001-06-26 2003-01-03 Decode Genetics Ehf. Nucleic acids encoding g protein-coupled receptors
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
ATE305300T1 (en) 2001-07-02 2005-10-15 Sinan Tas USE OF CYCLOPAMINE TO TREAT BASAL CELL CARCINOMA AND OTHER TUMORS
AU2002317105A1 (en) 2001-07-05 2003-01-21 University Of British Columbia Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
JP2004536877A (en) 2001-07-25 2004-12-09 ロランティス リミテッド Notch signaling modulators for immunotherapy
EP1482928B1 (en) 2001-07-27 2009-09-23 Curis, Inc. Mediators of hedgehog signaling pathways,compositions and uses related thereto
CN1304390C (en) 2001-08-03 2007-03-14 先灵公司 Novel gamma secretase inhibitors
AR035260A1 (en) 2001-08-03 2004-05-05 Schering Corp DERIVATIVES OF REPLACED AMINO PIPERIDINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES AS INHIBITORS OF THE SECRETASE RANGE, AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
US20050137130A1 (en) 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
US7053547B2 (en) 2001-11-29 2006-05-30 Universal Display Corporation Increased emission efficiency in organic light-emitting devices on high-index substrates
CA2469204A1 (en) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
AU2003206756A1 (en) 2002-01-17 2003-07-30 Kobenhavns Universitet A suprabasal breast cell line with stem cell properties
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
US20050089896A1 (en) 2003-02-18 2005-04-28 Roy Frans V. Method to control tumor progression and invasiveness
US20030185829A1 (en) 2002-03-12 2003-10-02 Erich Koller Jagged 2 inhibitors for inducing apoptosis
DK1918386T3 (en) 2002-03-13 2012-01-02 Genomic Health Inc Gene expression profiles in tumor tissue biopsies
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
EP1534331B1 (en) 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
GB0218879D0 (en) 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
JP2006515177A (en) 2002-09-10 2006-05-25 ロランティス リミテッド Pharmaceutical composition comprising Notch ligand protein and medical treatment
GB0221952D0 (en) 2002-09-20 2002-10-30 Novartis Forschungsstiftung Wnt mediated ErbB1 signalling,compositions and uses related thereto
US20040247593A1 (en) 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc Compositions and methods for the treatment of immune related diseases
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20040219579A1 (en) 2003-02-19 2004-11-04 Natasha Aziz Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP2233926A3 (en) 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
WO2004097030A2 (en) 2003-04-28 2004-11-11 Bristol-Myers Squibb Company Prognostic breast cancer biomarkers
EP1627081A4 (en) 2003-05-02 2006-08-16 Health Research Inc Use of jag2 expression in diagnosis of plasma cell disorders
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
US6894522B2 (en) * 2003-10-06 2005-05-17 International Business Machines Corporation Specific site backside underlaying and micromasking method for electrical characterization of semiconductor devices
US20050232927A1 (en) 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20050221476A1 (en) 2004-03-18 2005-10-06 Arindom Sen Chemical dissociation of cell aggregates
NZ551828A (en) 2004-05-12 2009-03-31 Inst Medical W & E Hall A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
WO2005116236A2 (en) 2004-05-14 2005-12-08 The Regents Of The University Of California Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
CA2579078C (en) 2004-08-27 2016-11-22 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
WO2006027693A2 (en) 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
AU2005302846A1 (en) 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US7714014B2 (en) 2005-12-09 2010-05-11 The Regents Of The University Of California Targeting GLI proteins in human cancer by small molecules
PT1962895E (en) * 2005-12-16 2013-03-28 Regeneron Pharma Therapeutic use of a dll4 antagonist and a vegf inhibitor for inhibiting tumor growth
WO2008121102A2 (en) 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
KR20090016762A (en) 2006-06-06 2009-02-17 제넨테크, 인크. Compositions and methods for modulating vascular development
US20080187938A1 (en) 2006-09-22 2008-08-07 The Regents Of The University Of Michigan ALDH1 As A Cancer Stem Cell Marker
US7700113B2 (en) 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
AU2007309229B8 (en) 2006-10-19 2013-05-09 Genentech, Inc. Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
ITRM20060583A1 (en) 2006-10-27 2008-04-28 Francesco Bistoni USE OF THE TIMAMA ALFA 1 FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND CARE OF ALLERGIES
WO2008070042A2 (en) 2006-12-04 2008-06-12 Medimmune, Inc. High potency recombinant antibodies, methods for producing them and use in cancer therapy
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
TWI419904B (en) 2006-12-18 2013-12-21 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP2010517944A (en) 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー DLL4 signaling inhibitor and use thereof
WO2008108910A2 (en) 2007-03-05 2008-09-12 Board Of Regents, The University Of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
PE20090321A1 (en) * 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
AU2007356840B2 (en) 2007-07-25 2013-07-18 Alma Mater Studiorum - Universita Di Bologna Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma
WO2009025867A2 (en) 2007-08-23 2009-02-26 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
WO2009075565A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
CN102112490B (en) * 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1 receptor binding agents and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037004A1 (en) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
WO1998057621A1 (en) * 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GUNTHERT U ET AL: "A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA CELLS", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 65, no. 1, 5 April 1991 (1991-04-05), pages 13 - 24, XP000470199, ISSN: 0092-8674 *
HAMBURGER A W ET AL: "PRIMARY BIOASSAY OF HUMAN TUMOR STEM CELLS", SCIENCE (WASHINGTON D C), vol. 197, no. 4302, 1977, pages 461 - 463, XP001094575, ISSN: 0036-8075 *
KUMMERMEHR JOHANN ET AL: "Tumour stem cells.", 1997, STEM CELLS., PAGE(S) 363-399, ACADEMIC PRESS LTD.;ACADEMIC PRESS, INC. 14 BELGRAVE SQUARE, 24-28 OVAL ROAD, LONDON NW1 70X, ENGLAND, UK; 1250 SIXTH AVE., SAN DIEGO, CALIFORNIA 92101, USA, ISBN: 0-12-563455-2, XP001093829 *
LI LINGHENG ET AL: "Cloning, characterization, and the complete 56.8-kilobase DNA sequence of the human NOTCH4 gene", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 51, no. 1, 1 July 1998 (1998-07-01), pages 45 - 58, XP002172754, ISSN: 0888-7543 *
REYA T ET AL: "Stem cells, cancer, and cancer stem cells.", NATURE. ENGLAND 1 NOV 2001, vol. 414, no. 6859, 1 November 2001 (2001-11-01), pages 105 - 111, XP002206733, ISSN: 0028-0836 *
SUGAYA KIMIHIKO ET AL: "Gene organization of human NOTCH4 and (CTG)-n polymorphism in this human counterpart gene of mouse proto-oncogene Int3", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 189, no. 2, 1997, pages 235 - 244, XP002178175, ISSN: 0378-1119 *
VORMOOR JOSEF ET AL: "Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice.", PEDIATRIC RESEARCH, vol. 49, no. 3, March 2001 (2001-03-01), pages 332 - 341, XP001094985, ISSN: 0031-3998 *

Also Published As

Publication number Publication date
EP2359863A3 (en) 2012-08-15
AU7813401A (en) 2002-02-18
JP5352037B2 (en) 2013-11-27
WO2002012447A2 (en) 2002-02-14
US20070231325A1 (en) 2007-10-04
US7850961B2 (en) 2010-12-14
US9089556B2 (en) 2015-07-28
US7115360B2 (en) 2006-10-03
US20110033481A1 (en) 2011-02-10
AU2001278134B2 (en) 2007-10-11
US20120295350A1 (en) 2012-11-22
US20170175083A1 (en) 2017-06-22
US9492538B2 (en) 2016-11-15
US20020119565A1 (en) 2002-08-29
US20060073125A1 (en) 2006-04-06
US20070212737A1 (en) 2007-09-13
US20070259969A1 (en) 2007-11-08
ES2553796T3 (en) 2015-12-11
US20040037815A1 (en) 2004-02-26
EP1343871B1 (en) 2015-10-07
US20090004205A1 (en) 2009-01-01
JP2004527211A (en) 2004-09-09
EP2359863A2 (en) 2011-08-24
EP1343871A2 (en) 2003-09-17
CA2417909C (en) 2015-09-29
US20060051325A1 (en) 2006-03-09
US7754206B2 (en) 2010-07-13
WO2002012447B1 (en) 2003-07-03
EP2359863B1 (en) 2018-11-14
US10227567B2 (en) 2019-03-12
US20070190647A1 (en) 2007-08-16
US20140037644A1 (en) 2014-02-06
US6984522B2 (en) 2006-01-10
CA2417909A1 (en) 2002-02-14
US7713710B2 (en) 2010-05-11

Similar Documents

Publication Publication Date Title
WO2002012447A3 (en) Isolation and use of solid tumor stem cells
Yutin et al. A genomic update on clostridial phylogeny: G ram‐negative spore formers and other misplaced clostridia
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
WO2002047474A1 (en) Transgenic animal expressing hla-a24 and utilization thereof
EP2330197A3 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
TW200611910A (en) Interferon-alpha polypeptides and conjugates
EP1352961A4 (en) Synovial cell protein
EP1930407A4 (en) Novel bacterium belonging to the genus bifidobacterium and utilization of the same
MXPA02012743A (en) Il-17 molecules and uses thereof.
MXPA03002783A (en) Measurement of fuel cell impedance.
MA29612B1 (en) COMPOUNDS AND METHODS FOR MODULATING KINASE AND RELATED INSTRUCTIONS
NO995475D0 (en) Chemical connections
NL1021701A1 (en) PEM fuel cell.
GB2424947A (en) Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells
Cao et al. Genetic Incorporation of ϵ‐N‐Benzoyllysine by Engineering Methanomethylophilus alvus Pyrrolysyl‐tRNA Synthetase
WO2003008553A3 (en) Proteins associated with cell growth, differentiation, and death
WO2000044900A3 (en) Nucleic-acid binding proteins
PT1186292E (en) SOLID PREPARATIONS WITH MULTINUCLEAR STRUCTURE
NO20012100D0 (en) Pyrano, piperidino and thiopyrano compounds and methods of use
AU1935399A (en) Nucleotide and protein sequence of mammastatin and methods of use
Sakai et al. Coexistence of spindle cell lipoma and ordinary lipoma
WO2005077983A3 (en) Modulating p38 kinase activity
WO2000040722A3 (en) Insulin-synthesis genes
WO1999047709A3 (en) Methods for identifying anti-cancer agents
WO1999061039A3 (en) Novel composition for modulating ischemic cell death

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001278134

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2417909

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002517738

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001956101

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

B Later publication of amended claims

Free format text: 20030121

WWE Wipo information: entry into national phase

Ref document number: 10343692

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001956101

Country of ref document: EP